Drug intelligence / Profile preview

IVF002

Development stage: Unknown
Lead developer: Pantec Biosolutions
Modality: Recombinant Proteins and Enzymes

Overview

IVF002 is an investigational follicle-stimulating hormone (FSH)–based fertility drug being developed as a novel product for controlled ovarian stimulation in women undergoing in vitro fertilization (IVF). It is designed to stimulate ovarian follicle growth via activation of the follicle-stimulating hormone receptor on granulosa cells, promoting multi-follicular development required for oocyte retrieval in assisted reproductive technologies. Early clinical work by Pantec Biosolutions has shown successful follicle stimulation and achievement of at least one pregnancy in exploratory proof-of-concept studies in IVF patients, with the program advanced to phase 2 development for infertility treatment.[7]

Targets

FSHR (Follicle-stimulating hormone receptor)

Beyond the preview

Go deeper on IVF002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVF002.

Explore the full profile